Methods and assays for treating subjects with SHANK3 deletion, mutation or reduced expression
US8691762B2 · kind B2 · utility
3Cited by
1References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 21, 2012 |
| Grant date | Apr 8, 2014 |
| Priority date | — |
| Expiry date | Mar 21, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/72
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and assays are disclosed for treating subjects with 22q13 deletion syndrome or SHANK3 deletion or duplication, mutation or reduced expression, where the methods comprise administering to the subject insulin-like growth factor 1 (IGF-1), IGF-1-derived peptide or analog, growth hormone, an AMPAkine, a compound that directly or indirectly enhances glutamate neurotransmission, including by inhibiting inhibitory (most typically GABA) transmission, or an agent that activates the growth hormone receptor or the insulin-like growth factor 1 (IGF-1) receptor, or a downstream signaling pathway thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.